Results 261 to 270 of about 136,607 (334)

Consulting, diagnosis and treatment patterns in migraine: results from the Migraine in Poland cross-sectional survey. [PDF]

Ther Adv Neurol Disord
Waliszewska-Prosół M, Straburzyński M, Budrewicz S, Marschollek K, Nowaczewska M, Gać P, Lipton RB.   +6 more
europepmc   +1 more source

Acetyl Salicylic Acid, COX‐2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population‐Based Cohort

Cancer Reports, Volume 8, Issue 7, July 2025.
ABSTRACT Background Non‐steroidal anti‐inflammatory drugs (NSAIDs), particularly acetylsalicylic acid (ASA), have been associated with reduced breast cancer (BCa) mortality. While overexpression of cyclooxygenase‐2 (COX‐2) correlates with poorer prognosis in BCa, COX‐2 inhibitors (coxibs) have not demonstrated a survival advantage.
M. Malin, M. Murto, O. Arponen, A. Jukkola, A. Siltari, M. Artama, K. Visvanathan, T. Murtola   +7 more
wiley   +1 more source

Mitigating renal dysfunction in liver cirrhosis: Therapeutic role of ferrous sulphate, folic acid, and its co-administration. [PDF]

Toxicol Rep
Dash D, Rai RK, Koiri RK.
europepmc   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, Volume 14, Issue 7, Page 528-541, July 2025.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants

Clinical Pharmacology in Drug Development, Volume 14, Issue 7, Page 511-519, July 2025.
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley   +1 more source

Relationship of Reduced Pain Intensity and Improved Quality-of-Life with Menstrual Migraine with Aspirin, Acetaminophen, and Caffeine Combination. [PDF]

Healthcare (Basel)
Mitra A, Araga M, Aher A, Xu J, Shanga G, Franks B, Petruschke R.   +6 more
europepmc   +1 more source

Comparative Analysis of Lysophosphatidic Acid Levels in Fibromyalgia and Other Painful Conditions in Female Patients

European Journal of Pain, Volume 29, Issue 6, July 2025.
ABSTRACT Background Previous work found a decrease in lysophosphatidylcholines (LPCs) in fibromyalgia (FM) serum, prompting the hypothesis that this decrease could be due to increased conversion of LPC to lysophosphatidic acid (LPA) through autotaxin (ATX). LPA has pronociceptive functions, and increased LPA levels could modulate FM pain.
Joana Menezes, Jenny E. Jakobsson, Alex Bersellini Farinotti, Emerson Krock, Matthew A. Hunt, Nils Simon, Sigita Venckute Larsson, Lars Tanum, Kim Kultima, Eva Kosek, Camilla I. Svensson   +10 more
wiley   +1 more source

Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. [PDF]

Anesthesiology
Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG.   +13 more
europepmc   +1 more source